ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

ImageneBio IncNASDAQ: IMA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $11.91M rose 68.2% year over year, ahead of the +53.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 49.9% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.

Context

  • Operating expenses amounted to 6027.3% of revenue in FY2025, up 4870.1 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +68.2% holds above the trailing-twelve-month pace of +53.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.91M+49.9% QoQ
Last fiscal yearDec 2025
$48.22M+19.1% YoY
LTMMar 2026
$55.15M+53.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.2%——
1 year+19.1%——
3-year CAGR+29.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
48.22M USD
Year-over-year change
+19.1%
4-year CAGR
+27.9%

Operating Expenses vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +53.1% is the highest of 9, against a peer median of -17.6%.
  • Over three fiscal years its annual growth of +29.5% compares with a peer median of +9.6%.
IMA Competitors
Operating Expenses for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$213.41M USD-32.3%+2.0%214.2%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$91.4M USD+21.9%+10.8%—
CNTBConnect Biopharma Holdings LimitedFY2025$58.14M USD+19.9%-21.3%90840.6%
IMAImageneBio IncLTM Mar 2026$55.15M USD+53.1%+29.5%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$54.82M USD-4.8%-4.7%769.8%
STTKShattuck Labs, Inc.LTM Mar 2026$51.84M USD-32.4%+34.1%5184.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$47.61M USD-33.8%+48.8%—
CNTXContext Therapeutics Inc.LTM Mar 2026$43.51M USD+37.6%+37.2%—
IFRXInflaRx N.V.LTM Mar 2026€35.14M EUR-30.5%+8.4%119798.7%
Peer median (excluding IMA) —-17.6%+9.6%5184.4%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.